It has been observed that the expression of G9a is upregulated in a number of cancers, including aggressive lung cancer, multiple myeloma, aggressive ovarian carcinoma, brain cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and malignant melanoma (Wozniak et al., 2007; Gao et al., 2013; Hua et al., 2014; Lehnertz et al., 2014; Hu et al., 2019; Dang et al., 2020). Here, EHMT2 is linked to cancer.